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Diagnosis and treatment of malignant 
PEComa tumours 
ABSTRACT 
PEComa (PEC tumours; perivascular epithelioid cell tumours) is a family of rare tumours of mesenchymal origin, 
consisting of epithelial perivascular cells expressing melanocytic and myioid markers. This group includes benign 
tumours — such as angiomyolipoma (AML) of the kidney, and poorly differentiated malignant PEComa tumours with 
potential for an aggressive clinical course, which is the main focus of this review. PEComas are most often diagnosed 
in middle-aged women as extensive tumours located in the abdominal cavity or pelvis, manifesting as pain and 
complaints related to pressure on nearby organs. PEComa tumours should be differentiated from gastrointestinal 
stromal tumours (GIST), leiomyosarcoma, melanoma metastasis, chromophobic renal cell carcinoma, clear cell 
sarcoma, and other clear cell component tumours. Somatic inactivating mutations within the TSC1/TSC2 genes, 
resulting in excessive activation of the mTORC1 complex, are characteristic for this group of tumour. Recently, 
a separate PEComa subgroup has been distinguished, characterised by the presence of the TFE3 gene fusion, 
which also causes increased activity of the mTOR signalling pathway. Negative prognostic factors that indicate 
an increased risk of PEComa malignant biology are most often: tumour size > 5 cm, increased cytological and 
nuclear atypia, infiltration of surrounding tissues and blood vessels, presence of necrosis, and high mitotic activity. 
Radical resection remains the primary treatment method for PEComas because these tumours are characterised by 
high resistance to radiation and chemotherapy. In the case of locally advanced or metastatic disease, only single 
reports of short-term responses to palliative chemotherapy containing doxorubicin, gemcitabine, or ifosfamide are 
available in the literature. There are an increasing number of reports, in the form of several case reports and a few 
retrospective analyses, about the potential effectiveness of using mTOR inhibitors in unresectable cases. These 
drugs result in a reduction in primary tumour size and metastasis, as well as symptom relief, with controllable side 
effects. Unfortunately, case reports of complete resistance to mTOR inhibitor therapy are also available.
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Introduction
PEComa (PEC tumours; perivascular epithelioid cell 
tumours) is a family of rare tumours of mesenchymal 
origin composed of perivascular epithelioid cells (PEC) 
[1]. This group includes angiomyolipomas (AML), 
clear-cell sugar tumours (CCST) — pulmonary and 
extrapulmonary (PEST, primary extrapulmonary sugar 
tumour), lymphangioleiomyomatosis (LAM), clear-cell 
myomelanocytic tumours (CCMMT), and primary cu-
taneous PEComas (CCCMT, cutaneous clear cell myo-
melanocytic tumours). PEComa NOS (not otherwise 
specified) is a joint term for a broad group of tumours 
with perivascular epithelioid differentiation, not qualify-
ing for the remaining subgroups of the PEComa family 
(AML, LAM, CCST, CCMMT). According to the WHO 
classification, in the PECOma NOS both benign PEC-
oma NOS as well as clinically challenging tumours with 
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a higher degree of malignancy are included (malignant 
PEComa NOS). A malignant PEComa encountered by 
clinical oncologists in their practice is abdominopelvic 
perivascular epithelioid cell sarcoma — the so-called 
malignant PEComa [2, 3]. In the largest analysis per-
formed so far encompassing 234 PEComa NOS cases 
described in the literature, epithelioid AML subtypes 
occurring outside the kidneys were also qualified [3]. 
In a collective analysis of 100 cases of PEComa-NOS, 
38 cases were locally advanced with an infiltration of 
surrounding organs, and four patients developed metas-
tases — these patients were qualified into the malignant 
PEComa group (Figure 1) [4]. Altogether fewer than 
100 cases of malignant PEComa have been described in 
the literature [3, 5], and 13 of them concerned changes 
within bones [6].
Epidemiology
The age of the patients at the time of PEComa diag-
nosis is most commonly in the range of 38.9–56 years 
[7, 8], but PEComa cases in children have also been 
described [9, 10]. All reviews indicate more common 
PEComa occurrence in women (54–86.9% of cases) [11, 
12], also after exclusion of sex-specific locations from 
the analysis [3].
Anatomical location
Among the most common locations for PEComa 
development are the uterus, skin, the liver, and the 
colon [3, 13]. Moreover, large malignant PEComas are 
diagnosed especially in the extraperitoneal space [14]. 
Many anatomical locations have been described for 
PEComas. In a large analysis 24 pancreatic PEComa 
cases were presented, of which half were localised in the 
head of the pancreas [12] and numerous PEComas of the 
digestive tract [11, 15], including the stomach [16], the 
ileus [17] and the colon [18]. Moreover, single cases in 
various locations have been described: the greater omen-
tum [19], the gall bladder [20], the common bile duct 
[21], the breast [22], the thigh bone [6], rib [23], skull 
base [24], heart [25], pericardium [26], the prostate [27, 
28], ovary [29], nasal cavity [30], throat [31], eye socket 
[10], urinary bladder [32], lung [33], and the groin [34]. 
Diagnosis
PEComa is quite often (approx. 20% of the cases) 
diagnosed by chance in an imaging examination per-
formed for other indications [12]. The symptomatic 
form, most commonly locally advanced, manifests by 
pain and discomfort in the area of the tumour and by 
weight loss [12, 35], and in the case of PEComa locali-
sed in the uterus by a bloody discharge [36]. A biopsy is 
required for the diagnosis. 
Metastases are most commonly described in the 
lungs — cases of pneumothorax caused by tumour 
infiltration [37], and in the liver and bones. Metastases 
to the extraperitoneal space have also been described 
as well as the central nervous system, ovary, adrenal 
glands, peritoneum, intestinal wall, skin, stomach, 
and lymph nodes [3, 4, 35, 37, 38]. For this reason, the 
diagnosis of malignant PEComa requires a complete 
evaluation of the staging as in the case of other sarcomas 
[39]. Dissemination in patients with primary tumours 
in the pelvis or lower limb first takes place to the lung 
(90%); 77.8% of tumours encompassing the kidneys 
and the mesentery first metastasise to the liver, and in 
turn tumours in the adrenal glands and extraperitoneal 
tissues initially give metastases to the peritoneum and 
lungs [40]. As metastases often occur after many years 
and predictive markers for their development are not 
known, patients after PEComa resection, especially of 
tumours > 8 cm, require observation for many years 
after surgical treatment [4]. Metastases in patients with 
PEComa can develop even up to 10 years after resection 
of the primary tumour [41].  
Pathomorphology
PEC (perivascular epithelioid cells) do not have 
a corresponding normal cell type and simultaneously 
express differentiation markers for muscle cells and 
melanocytes. PEComas are composed of epithelioid 
and spindle-shaped cells with a light and eosinophilic 
cytoplasm with a sporadic presence of granulari-
ties. Cell nuclei are small and cylindrical; the nucleolus 
is rarely visible. The cells form nests or bands, often 
radially surrounding blood vessels [42]. In PEComa 
cells from the colon obtained by thin needle biopsy 
the presence of eosinophilic cytoplasmic inclusions 
has been described [43]. Elongated fusiform cells in 
PEComas are characterised by distinct fibres specific 
for smooth muscle, while the epithelioid component 
in general does not contain a large amount of such 
fibres. A PEComa may thus be composed of fusiform 
cells with elongated nuclei and thus present a myoid 
phenotype, or it may contain cells with a clearly eo-
sinophilic cytoplasm and a more visible epithelioid 
phenotype; both these types of cells occur next to each 
other in the tumour (Fig. 1) [4].
In immunohistochemical staining typically co-ex-
pression of melanocytic markers is observed:
 — HMB-45 in 92–100% [36, 44, 45];
 — Melan A/Mart1 in 23–88% [36, 46];
 — transcriptional factor MITF; nuclear expression in 
50–92% [36, 44];
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Figure 1. Malignant tumors of the PEComa family. A. As per definition, malignant PEComas is characterized by infiltrative growth type 
(HE, 40×); B. In addition, they PEComas characterized by high grade cytological atypia (HE, 400×); C. Tumor cells express HMB-45, which, 
together with SMA and Cathepsin K, are typical immunohistochemical markers (600×); D. Malignant PEComa with the presence of 
cells with pale and granular abundant cytoplasm (HE, 400×); E. Strong expression of Cathepsin K (200×); F. Strong nuclear expression 
of TFE3 (200×) — rearrangement of the TFE3 gene confirmed by fluorescence in situ hybridization and next generation sequencing
 — S100; rare nuclear and cytoplasmic expression in 
8–33% [44, 46];
and smooth muscle: 
 — desmin 36–100% [36, 44];
 — smooth muscle actin (SMA) 59–93% [4, 44, 46]; 
 — caldesmon 75–92% [36, 45].
Among additional PEComa markers cathepsin K 
is mentioned; its expression was observed in all analysed 
cases [45, 47], and transcriptional factor TFE3 (tran-
scription factor binding to IGHM enhancer 3) was 
observed in 29–38% of cases regardless of the rear-
rangement of the TFE3 gene [36, 44]. PNL2 has been 
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proposed as a new marker with high sensitivity and 
specificity in the differentiation of PEComa and AML 
(expression described in 89% of cases) from other neo-
plasms derived from kidneys, which do not express this 
marker [48]. In immunohistochemical analysis PEComas 
also stain positive for vimentin, CD-31, and CD-34 and 
are negative for CgA (chromogranin A), Syn (synap-
tophysin), CK (creatine kinase), CD117, CD10, AFP 
(alpha-fetoprotein), and EMA (epithelial membrane 
antigen). There are single reports about positive results 
of staining for progesterone receptor [49]. Cytoplasmic 
expression of CD10, a marker used in differential diag-
nosis of renal cell carcinoma metastases to the skin, has 
also been detected in skin PEComas [50]. In four cases of 
malignant-PEComa-NOS formed in the colon, the thigh, 
elbow, and bladder a strong nuclear overexpression of 
cyclin D1 was observed [51].
Macroscopically PEComa tumours are pink, yel-
low-brown, or white in cross section, with a differenti-
ated consistency. In about 20% of cases, bleeding into 
the tumour or the presence of necrosis are observed 
[45]. The tumour capsule, typical for sarcomas, is 
absent, but the tumours are described as well limited 
from surrounding tissue [11, 35]. PEComa tumours are 
characterised by a rich vascularisation from branching 
capillaries to thicker arterioles, often with a hyalinised 
wall [42]. In 13–19% of PEComa cases an increased 
hyalinisation of the stroma is observed and the lack of 
the rich vascularisation typical for classical cases; this 
variant has been described as the sclerosing variant 
[36, 46]. Malignant PEComa is characterised by a high 
degree of histological malignancy, high cellularity, a high 
mitotic index (> 1/50 HPF), the presence of necrosis, 
and the possibility of infiltration of surrounding tissues 
and blood and lymphatic vessels [44]. 
The basic pathological differential diagnosis for 
PEComa NOS (summarised in Table 1) encompasses: 
gastrointestinal stromal tumours (GIST), melanoma, 
renal cell, and adrenocortical carcinoma, especially the 
chromophobic type, clear cell sarcoma of tendon and 
aponeurosis — melanoma of the soft parts (CCS), alve-
olar soft part sarcoma (ASPS) [8, 52], paraganglioma, 
angiomyolipoma, and also gynaecological tumours such 
as endometrial stromal sarcoma with clear cell features 
or uterine tumour resembling sex cord tumour and other 
tumours with a clear cell component [4]. It is also im-
portant to distinguish them from tumours derived from 
smooth muscle (epithelioid leiomyosarcoma — LMS 
and epithelioid leiomyoma). 
The diffuse and multimarker expression of proteins 
of melanocytic differentiation, which does not occur in 
other sarcomas, is highly indicative for the diagnosis of 
PEComas. Focal or weakly positive results of staining do 
not justify a PEComa diagnosis. Diagnosis of an angio-
myolipoma can be excluded if neither lipid elements nor 
a biphasic cell population are present. However, PEC-
oma and a monophasic epithelioid angiomyolipoma are 
probably very close diagnoses. An endometrial stromal 
Table 1. Pathological differential diagnosis of PEComa NOS
Unit Morphology Immunohistochemical markers Other characteristic 
properties HMB-45, 
Melan A
CD117 S100 CD10 SMA TFE3
PEComa Perivascular proliferation of 
epithelioid and fusiform cells with 
light eosinophilic cytoplasm with 
granularities, nucleoli are visible 
+ ± ± ± + ±
GIST Epithelioid and fusiform cells 
with light eosinophilic cytoplasm 
without granularities
– + 
(together 
with CD34)
– – – – c-kit and PDGFA 
mutations
Melanoma Cells of different shapes.  
No clear nucleoli
+ – + – – – BRAF mutations in 
approx. 50% of patients
Chromo-
phobic RCC
Richly vascularised; epithelioid 
cells
– + – + – –
CCS Nests of spherical or epithelioid 
cells, giant multinuclear cells 
present
+ – + – – – Gene fusions: t(2:22)
(q34;q12)(EWS-CREB11) 
t(12;22)(q13;q13)(EWS-
-ATF1)
ASPS Cytoplasmic granularities,  
no epithelioid cells
– – – – ± + Translocations t(X; 17)
LMS Epithelioid and fusiform cells – ± ± + + –
ASPS — alveolar soft part sarcoma; CCS — clear cell sarcoma; GIST — gastrointestinal stromal tumour; RCC — renal cell carcinoma; SMA — smooth muscle actin
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sarcoma can be excluded due to the presence of a clear 
perivascular distribution of tumour cells and a diffuse, 
and not focal, positive staining HMB-45. PEComa 
can be distinguished from paraganglioma because the 
former is negative for staining for chromogranin A, syn-
aptophysin, and protein S100, and the latter more com-
monly grows in the form of organoids. The expression of 
melanocyte markers (HMB-45 and MART-1/Melan-A) 
and the lack of immunoreactivity to cytokeratins and 
renal cell carcinoma counter a diagnosis of cancer and 
help to recognise a PEComa [51].
Genetics
In approx. 80% of PEComa cases deletions and/or loss 
of heterozygosity (LOH) are observed in the 16p13.3 re-
gion, at locus TSC2, leading to the loss of tuberin activity 
[7, 53]. Sporadically LOH is observed in the 9q34 region, 
locus TSC1, encoding hamartin [54]. Both proteins parti-
cipate in forming a complex with GTPase activity, acting 
as an inhibitor of the mTOR (mTOR/S6K1/4E-BP1) 
signal pathway. Activation of the mTOR pathway leads 
to increased proliferation of cells and their differentiation 
into myocytes. The loss of the function of tuberin and/or 
hamartin leads to an excessive activity of the mTOR 
serine/threonine kinase, which is a target for the use of 
mTOR inhibitors in the therapy of patients with advanced 
PEComa [55]. These perturbations are often accompa-
nied by mutations of the TP53 gene, which is described in 
63% of the cases in which this was analysed [7].
In spite of the frequent presence of TSC2 somatic 
mutations, the occurrence of PEComa NOS/malignant 
PEComa is less tightly connected to tuberous sclerosis 
— a genetic syndrome caused by a germ-line mutation 
inactivating the TSC1 or TSC2 genes — in comparison 
to the remaining tumours from this family, e.g. LAM 
or AML. In the literature tuberous sclerosis occurred 
only among 0–6.25% of patients with PEComa [36, 44].
In recent years, taking into consideration molecular 
investigations, a second form of PEComa, characterised 
by rearrangements of the TFE3 gene (Xp11.23) has been 
distinguished [7]. TFE3 rearrangements were described 
earlier in renal cell carcinoma [56] and are also chara-
cteristic for alveolar soft part sarcoma [57]. Its product 
is a transcription factor of the MiTF/TFE family regu-
lating the expression of genes dependent on the signal 
pathway of transforming growth factor b (TGF-b) [58]. 
Moreover, TFE3 takes part in the regulation of cellular 
metabolism via stimulation of lysosome formation and 
modification of the response to oxidative stress and 
increasing autophagy processes, resulting in activation 
of the mTORC1 signal pathway [59, 60]. For PEComa 
SFPQ/PSF-TFE3 and DVL2-TFE3 fusions have been 
described [7, 61]. 
TSC2 mutations and TFE3 gene rearrangements 
are mutually exclusive [7]. PEComa with a TFE3 gene 
rearrangement has been described as differing in mor-
phology, with a preponderance of epithelioid cells with 
a vesicular architecture and the lack of fusiform cells and 
no characteristic vascularisation. Lack of expression of 
smooth muscle actin (SMA) and desmin have also been 
observed [62]. However, the analysis only encompassed 
four cases, and in the literature there is also a case of 
a PEComa with a TFE3 gene fusion with morphological 
properties typical for the classical form [42]. 
Among rare gene rearrangements described in 
PEComas are two cases of RAD51B fusions with 
RRAGB/OPHN1 in a uterine PEComa and two cases 
of HTR4-ST3GAL1 and RASSF1-PDZRN3 fusions [7]. 
One case of malignant PEComa has been described in 
which next generation sequencing indicated a nonsense 
mutation (E1413*) in the ATRX gene (alpha thalassae-
mia-mental retardation, X linked) as the only genetic 
perturbation [63]. The loss of ATRX protein expres-
sion had been observed earlier in poorly differentiated 
soft tissue sarcomas [64] and was correlated with the 
phenomenon of alternative telomere elongation in 
leiomyosarcoma [65].
Treatment of locally advanced and 
metastatic disease 
Radical resection is the mainstay of PEComa treat-
ment because these tumours are characterised by resis-
tance to chemotherapy and radiotherapy [3, 66]. In the 
described cases also the mastectomy of metastatic foci 
(lung, kidney, liver) permitted long-term control of the 
disease [4]. Because of the overarching importance of 
surgical treatment in order to obtain long-term survival, 
patients with initially recognised advanced disease have 
unfavourable prognoses because so far the importance 
and/or significance of adjuvant or neoadjuvant chemo-
therapeutic treatment has not been proven and it is cur-
rently not recommended, with the exception of clinical 
research protocols and application in reference centres 
[67]. A response to neoadjuvant stereotactic radiothera-
py (SBRT; eight fractions of 7.5 Gy each) has also been 
observed in the case of a non-resectable liver PEComa. 
A decrease in the tumour size enabled radical resection, 
and the patient was disease-free after 21 months [68]. 
Chemotherapy has also been described as strongly de-
creasing the vascularisation but not the tumour size for 
PEComa (ifosfamide + vincristine + dactinomycin), 
which gives less blood loss during subsequent resection 
[51]. Three-component chemotherapy (epirubicin with 
cisplatin and ifosfamide) applied as a neoadjuvant al-
lowed a decrease of tumour mass and resectability of 
a mass in the pelvis [69]. 
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Classical palliative chemotherapy yields few ob-
jective responses, although the use of Adriamycin in 
monotherapy has been described, as well as high dose 
ifosfamide, gemcitabine with docetaxel, and dacarbazine 
[67]. In a retrospective analysis of 53 patients with locally 
advanced or metastatic PEComa, the objective response 
rate (ORR) to chemotherapy based on gemcitabine or 
anthracyclines was only obtained in a small percentage 
of the patients (respectively, ORR = 20% and 13%), and 
progression-free survival (PFS) was: 3.4 and 3.2 months 
[70]. Moreover, only single cases of a response to 
doxorubicin and ifosfamide treatment were observed, 
e.g. a nine-month stabilisation of the disease obtained 
in a patient with a colon PEComa with metastases to 
the liver and a response in the form of a diminished 
mass of an upper limb PEComa by 80% after six cycles 
(PR, partial response) [71, 72]. Partial responses (PR) 
were also noted for dacarbazine treatment, complete 
responses (CR) for vincristine, and progression when 
imatinib treatment was used [51].
Because of frequent genetic perturbations causing an 
increase in the activity of the mTOR signalling pathway, 
similarly as in other subgroups of this family of tumours, 
long-term response to treatment with mTOR inhibitors 
is observed [73]. Benson et al. (from the Royal Marsden 
Hospital) published a retrospective analysis of mTOR 
inhibitors in the treatment of advanced PEComas with 
metastases for 10 cases (eight women, two men, median 
age 47.5 years). Nine patients received sirolimus (me-
dian dose 4 mg/d p.o.) and one temsirolimus, at a dose 
of 25 mg/week intravenously. The reaction was evaluated 
according RECIST in 7/10 patients, PR was observed in 
50% of cases, SD in 10%, and PD in 10%. In the three 
remaining patients, rapid progression took place in the 
first days of the treatment. Among the nine patients 
receiving sirolimus, the drug dose was decreased in five, 
and in four the treatment was intermittently stopped 
because of undesirable effects. Treatment was stopped 
in seven patients, in six of them because of disease pro-
gression. The one-year survival rate was 78.8%, and the 
survival time median was 2.4 years, with median obser-
vation time of 1.9 years [74]. In a retrospective analysis, 
application of mTOR inhibitors in patients with locally 
advanced or metastatic PEComa was demonstrated 
(ORR: 41%, PFS: 9 months), compared to classical 
chemotherapy based on gemcitabine or anthracyclines 
(ORR: 20% and 13%, PFS: 3.4 and 3.2 months) [70]. 
In another analysis encompassing five patients with 
PEComa metastases in the digestive tract, treated with 
sirolimus or everolimus, a clinical response was obtained 
in four (observation period 1 to 47 months), and in 
one patient progression and death occurred 23 months 
after diagnosis [11]. The remaining data about the use 
of mTOR inhibitors in this group of patients are from 
descriptions of cases. A 20-month disease stabilisation 
(SD) was observed in a patient with a disseminated 
form of kidney PEComa treated with sirolimus [75]. The 
therapy was complicated by strong undesirable effects 
during the first month of treatment, linked to the level 
of the drug in the blood of 156.8 ng/ml; this disappeared 
during five weeks after adjusting the dose. A pancreatic 
PEComa has been described in which resection was not 
performed and therapy with sirolimus was introduced, 
obtaining a partial response, which was maintained for 
42 months [76]. A case of a patient with an advanced 
colon PEComa with metastases to the liver is known 
— after radical resection he received sirolimus as an 
adjuvant. In spite of treatment, local relapse occurred 
Figure 2. CT scan of PEComa — large pelvic and intraperitoneal tumours
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along with new liver metastases [72]. A 36-month 
stabilisation of the disease has also been described in 
a patient with kidney PEComa with metastases to the 
lung as a response to everolimus [77]. Italiano et al. 
described a response to temsirolimus treatment in a pa-
tient after resection of a uterine PEComa with a single 
lung metastasis. A decrease in tumour size by 35% was 
observed with a subsequent lobectomy. The patient 
remained disease free for nine months after the surgery 
with continued temsirolimus therapy [78]. 
In spite of promising responses, cases of resistance 
to mTOR inhibitors have also been described in com-
bination with resistance to chemotherapy or without it. 
Machado et al. described a case of resistance to both 
Adriamycin and ifosfamide in high doses as well as 
temsirolimus (SD for a period of five months), leading 
to the patient’s death 30 months after the diagnosis 
[67]. As markers of expected response to sirolimus and 
everolimus, the following are indicated: the presence 
of TSC1/TSC2 gene mutations and overexpression of 
ribosomal protein pS6-S235/236 [67]. Single cases of 
the use of this group of drugs in patients with PEComas 
described in the literature are summarised in Table 2. 
Regarding new drugs, recently a case of a one-year 
disease stabilisation in response to pazopanib combined 
with nivolumab has been described in an advanced 
PEComa of the lower limb with metastases to bones 
and lungs [63]. Potential benefits of using angiogenesis 
inhibitors in patients with advanced PEComa have been 
described, but only a very small percentage of objective 
responses have been achieved, mainly in the form of dis-
ease stabilisation: ORR = 8.3%, PFS = 5.4 months [70].
Survival — prognostic factors for 
PEComa-NOS
Among PEComa-NOS tumours, both clinically 
benign tumours as well as rapidly progressing tumours 
with disease dissemination are observed. Folpe et al. 
proposed the division of PEComas into three catego-
ries of risk: benign tumours, tumours with an uncertain 
malignancy potential, and malignant tumours, on the 
Table 3. Classification of PEComa NOS after [44]
Tumour size greater than 5 cm Benign 
< 2 high risk characteristics and size < 5 cm
High degree of histological malignancy  
and high cellularity
Uncertain malignancy potential
Size > 5 cm and no other high-risk characteristics OR nuclear 
pleomorphism/multinuclear giant cells
High mitotic index (> 1/50 HPF) Malignant
2 or more high-risk characteristicsPresence of necrosis
Infiltration of blood vessels
basis of the presence of the high-risk characteristics 
presented in Table 3 [44]. 
The prognostic suitability of the above-mentioned 
criteria was evaluated in a large review, encompassing 
234 PEComa NOS cases available in the literature [3]. 
Among tumours classified as benign according to the 
Folpe criteria no relapses of the disease were observed. 
However, among cases in which a relapse did occur, 
tumours classified as malignant constituted 81.6% 
(median time to relapse 23 months). In about 30% of 
all cases the tumours were malignant (local relapse 
or disease dissemination took place), and tumours 
evaluated as malignant according to Folpe consti-
tuted 51% of these tumours [3]. 10.6% of cases led 
to death because of the disease, and seven of them 
were diagnosed at the moment of dissemination or 
in a non-resectable stage, and in 13 relapse occurred 
after resection [3]. In the same paper a significant cor-
relation was demonstrated between tumour size over 
5 cm (p = 0.04, RR = 6.16, 95% Cl: 1.04–117.4), a high 
mitotic index (> 1/50 HPS) (p < 0.01, RR = 6.96, 95% 
Cl: 2.2–26.7), low degree of cellular differentiation 
— Grade 3 (p = 0.03, RR = 3.35, 95% Cl: 1.17–9.42), 
and a higher risk of PEComa relapse after resection [3]. 
The primary location in skin was linked to a lower risk 
of local relapse after resection. In 20 of the described 
cases not one relapsed (p = 0.002, RR = 6.2 × 10–7, 
95% Cl: not calculable), whereas relapse occurred in 
11.1% of cases located in the liver and in 33.3% of cases 
concerning extraperitoneal space [3]. 
In another analysis concerning PEComas localised 
in female sex organs, the following were among factors 
significantly correlated with a risk of recurrence or me-
tastases: size greater than 5 cm (p = 0.0048), presence 
of necrosis (p = 0.0014), infiltration of lymph vessels 
(p = 0.0006), pronounced nuclear atypia (p = 0.0192), 
and mitotic activity > 1/50 HPF (p = 0.011) [36]. In 
an investigation focused on digestive tract PEComas, 
there were distant metastases in 37% of patients, and 
a higher risk of their occurrence was correlated with the 
following: pronounced nuclear atypia (p = 0.0033), dis-
seminated pleomorphism (p = 0.02), and the presence 
of ≥ 2 mitoses/10 HPF (p = 0.0002) [11]. In another 
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analysis concerning digestive tract PEComa, local re-
lapse did not occur, and the presence of distant metas-
tases after resection was observed in 37.1% of patients, 
with a median of time to occurrence of metastases of 
six months [35]. 
In an analysis encompassing PEComas localised 
in female sex organs, 66% of cases were treated by 
surgery alone, and the average OS after resection was 
24.8 months. The age of the patient was a negative 
OS predictor. In patients with disseminated disease 
treated by surgery with adjuvant chemotherapy or 
radiotherapy the average OS was 17.8 months, and in 
those treated only systemically or by radiotherapy it was 
20.7 months. Patients with initial disseminated disease 
had a shorter OS regardless of the selected treatment 
method [35].
Summary 
Malignant PEComa tumours are most frequently 
diagnosed in middle-aged women as extensive tumours 
localised in the abdominal cavity or pelvis, presenting as 
pain from the tumour progression and problems linked to 
pressure on surrounding organs. These tumours, because 
of expression of melanocyte and myoid markers and the 
presence of poorly differentiated epithelioid cells, should 
be differentiated from stromal neoplasms of the digestive 
tract, leiomyosarcoma, melanoma metastases, chro-
mophobic type of renal cell carcinoma, clear cell sarcoma, 
and other neoplasms with a clear cell component. Somatic 
inactivating mutations within the TSC1/TSC2 genes and 
fusions of the TFE3 gene resulting in excessive activation 
of the mTORC1 complex are characteristic for these 
tumours. Among negative prognostic factors indicating 
an increased risk of malignant PEComa biology the most 
commonly included are: tumour size > 5 cm, pronounced 
cytological and nuclear atypia, infiltration of surrounding 
tissues and blood vessels, the presence of necrosis and 
high mitotic activity. Radical resection remains the main 
method of PEComa treatment because these tumours 
show a high resistance to radiotherapy and chemotherapy. 
There are increasing numbers of reports about the poten-
tial effectiveness of using mTOR inhibitors in non-resect-
able cases. These drugs cause a decrease in the size of the 
primary tumours and metastases and a decrease in the 
ailments, and the undesirable actions can be controlled. 
Unfortunately, cases have also been described of complete 
resistance to treatment with mTOR inhibitors.
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